Document is current
Any future updates will be listed below
-
Authors
Ferone, D.
Martin, W.
Williams, J.
Houchard, A. https://orcid.org/0000-0001-6248-8986
Pommie, C.
Ribeiro-Oliveira, A. Jr https://orcid.org/0000-0002-6114-5786
Grossman, A. B. https://orcid.org/0000-0003-1176-6186
-
Funding
Funding for this research was provided by:
Ipsen Biopharmaceuticals
- License Information
-
More Information
Article History
Received: 18 April 2023
Accepted: 13 July 2023
First Online: 8 August 2023
Declarations
:
: DF: Advisory Board Member; Novartis-AAA, Recordati, Camurus, Sandoz. Speaker; Novartis-AAA, Recordati, Camurus, Sandoz. WM: Has received speakers fees from Advanced Accelerators Applications (a Novartis company) and Ipsen. JW: Nothing to disclose. AH: Employee; Ipsen. Stock Owner; Ipsen. CP: Employee; Ipsen. Stock Owner; Ipsen. ARO: Employee; Ipsen. Stock Owner; Ipsen. ABG: Advisory Board fees; Ipsen; lecture fees from AAA (Novartis) and Recordati.
: The survey was conducted in compliance with relevant regulations, including the Epidemiological Studies published by the Council for International Organizations of Medical Sciences (12). Institutional Review Board review was not required due to the design of the study (simulated-use study and no involvement of patients).
